Lineage, Inc. Common Stock (LINE)vsVentas Inc (VTR)
LINE
Lineage, Inc. Common Stock
$42.63
-1.32%
REAL ESTATE · Cap: $11.14B
VTR
Ventas Inc
$79.09
+0.85%
REAL ESTATE · Cap: $41.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Ventas Inc generates 14% more annual revenue ($6.11B vs $5.36B). VTR leads profitability with a 4.3% profit margin vs -2.7%. VTR earns a higher WallStSmart Score of 51/100 (C-).
LINE
Avoid34
out of 100
Grade: F
VTR
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LINE.
Margin of Safety
-9.8%
Fair Value
$77.07
Current Price
$79.09
$2.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Revenue surging 21.9% year-over-year
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
Elevated debt levels
Expensive relative to growth rate
ROE of 2.0% — below average capital efficiency
4.3% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : VTR
The strongest argument for VTR centers on Price/Book, Revenue Growth. Revenue growth of 21.9% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : VTR
The primary concerns for VTR are PEG Ratio, Return on Equity, Profit Margin. A P/E of 153.8x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while VTR is a growth play — different risk/reward profiles.
VTR is growing revenue faster at 21.9% — sustainability is the question.
LINE generates stronger free cash flow (-55M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTR scores higher overall (51/100 vs 34/100) and 21.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.
Visit Website →Ventas Inc
REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA
Ventas, Inc. is a real estate investment trust specializing in the ownership and management of health care facilities in the United States, Canada and the United Kingdom.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?